Hexagon Capital Partners LLC Acquires 293 Shares of AstraZeneca PLC (NASDAQ:AZN)

Hexagon Capital Partners LLC lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 9.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,244 shares of the company’s stock after purchasing an additional 293 shares during the period. Hexagon Capital Partners LLC’s holdings in AstraZeneca were worth $220,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Beaird Harris Wealth Management LLC increased its position in shares of AstraZeneca by 8.9% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock worth $125,000 after acquiring an additional 151 shares during the period. Bryn Mawr Capital Management LLC raised its position in AstraZeneca by 0.3% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock valued at $4,167,000 after purchasing an additional 164 shares in the last quarter. Drive Wealth Management LLC lifted its holdings in shares of AstraZeneca by 4.5% in the 4th quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock worth $263,000 after buying an additional 170 shares during the period. GM Advisory Group LLC grew its position in shares of AstraZeneca by 3.5% during the 4th quarter. GM Advisory Group LLC now owns 5,015 shares of the company’s stock worth $338,000 after buying an additional 170 shares in the last quarter. Finally, Kathmere Capital Management LLC increased its stake in shares of AstraZeneca by 4.5% during the first quarter. Kathmere Capital Management LLC now owns 4,065 shares of the company’s stock valued at $275,000 after buying an additional 175 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AZN shares. BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Argus increased their target price on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. The Goldman Sachs Group initiated coverage on AstraZeneca in a report on Thursday, May 30th. They issued a “buy” rating and a $97.00 price target on the stock. Finally, Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average target price of $88.00.

AstraZeneca Stock Performance

Shares of AZN opened at $77.94 on Tuesday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $80.86. The stock has a fifty day moving average price of $77.68 and a 200-day moving average price of $70.51. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. The firm has a market cap of $241.65 billion, a PE ratio of 38.21, a P/E/G ratio of 1.40 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The business had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $11.92 billion. Equities research analysts predict that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.